BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting
BrainsWay presented 12-month durability data for its FDA-cleared SWIFT™ accelerated Deep TMS protocol at the 14th Annual Clinical TMS Society Meeting. The prospective study showed that over 80% of patients remained in remission at 12 months, with severe functional impairment dropping from 85% at baseline to 0%.
Key figures
- Drug Name
- SWIFT™ Deep TMS
- Consent rate
- 73%
- Remission rate 12m
- >80%
- Severe impairment 12m
- 0%
- Medication change rate
- <25%
- Pivotal trial patients
- 89
- Durability trial patients
- 65
- Severe impairment baseline
- 85%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.